Trials / Completed
CompletedNCT00159627
Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).
A Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study of the Effects of KW-3902 on Diuresis in Patients With Congestive Heart Failure (CHF) Refractory to High Dose Diuretic Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (planned)
- Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety of KW-3902IV compared to placebo and to determine the diuretic effect of KW-3902IV compared to placebo in patients hospitalized with volume overload due to CHF who are refractory to high dose diuretic therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KW-3902IV |
Timeline
- Start date
- 2004-08-01
- First posted
- 2005-09-12
- Last updated
- 2008-01-29
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00159627. Inclusion in this directory is not an endorsement.